← Back to Clinical Trials
Recruiting NCT05934851

NCT05934851 A Study Evaluating the Effect of Frozen-Section Directed Excision Surgery on Vulvar Dysplasia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05934851
Status Recruiting
Phase
Sponsor Wake Forest University Health Sciences
Condition Vulvar Neoplasm
Study Type INTERVENTIONAL
Enrollment 112 participants
Start Date 2023-11-07
Primary Completion 2026-08-01

Trial Parameters

Condition Vulvar Neoplasm
Sponsor Wake Forest University Health Sciences
Study Type INTERVENTIONAL
Phase N/A
Enrollment 112
Sex FEMALE
Min Age 18 Years
Max Age N/A
Start Date 2023-11-07
Completion 2026-08-01
Interventions
Frozen-Section Directed ExcisionWide Local Excision

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to compare "Frozen-Section Directed Excision", which has been a proven method of surgery used in dermatology, versus the current, standard method called "Wide Local Excision" to treat high-grade vulvar dysplasia.

Eligibility Criteria

Inclusion Criteria: 1. Written informed consent and HIPAA authorization for release of personal health information. 2. Age ≥ 18 years at the time of consent 3. Histological or cytological confirmation of VIN 2, VIN 3, VIN 2/3 or High-grade Dysplasia NOS with a planned excisional procedure, with high suspicion by the enrolling investigator that gross surgical margins of ≥ 3 mm can be achieved without laser or other destructive procedures 4. Surgery is expected to occur within 90 days from randomization 5. Ability to read and understand the English and/or Spanish language 6. As determined by the enrolling physician, ability and willingness of the subject to comply with study procedures for the entire length of the study 7. No known pregnancy Exclusion Criteria: 1. Excision is not possible due to anatomy (proximity to urethra/clitoris) 2. Known immunodeficiency syndrome 3. Immunosuppressant medications taken within the last 30 days (HIV, organ transplant recipient, chronic steroid use/imm

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology